Force, J. M., Howie, L. J., Abbott, S., Bentley, R. C., Marcom, P. K., Kimmick, G. G., … Nair, S. K. (2016). Increased FoxP3 and PD-L1 in non-pCR tissue from early stage HER2 positive breast cancer patients treated with trastuzumab-pertuzumab based regimens. In Journal of Clinical Oncology (Vol. 34, pp. 602–602). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2016.34.15_suppl.602

Force, Jeremy Meyer, Lynn Jackson Howie, Sara Abbott, Rex C. Bentley, Paul K. Marcom, Gretchen Genevieve Kimmick, Kelly E. Westbrook, et al. “Increased FoxP3 and PD-L1 in non-pCR tissue from early stage HER2 positive breast cancer patients treated with trastuzumab-pertuzumab based regimens.” In Journal of Clinical Oncology, 34:602–602. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.15_suppl.602.

Force JM, Howie LJ, Abbott S, Bentley RC, Marcom PK, Kimmick GG, et al. Increased FoxP3 and PD-L1 in non-pCR tissue from early stage HER2 positive breast cancer patients treated with trastuzumab-pertuzumab based regimens. In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2016. p. 602–602.

Force, Jeremy Meyer, et al. “Increased FoxP3 and PD-L1 in non-pCR tissue from early stage HER2 positive breast cancer patients treated with trastuzumab-pertuzumab based regimens.” Journal of Clinical Oncology, vol. 34, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2016, pp. 602–602. Crossref, doi:10.1200/jco.2016.34.15_suppl.602.

Force JM, Howie LJ, Abbott S, Bentley RC, Marcom PK, Kimmick GG, Westbrook KE, Parks M, Topping DL, Broadwater G, Blackwell KL, Nair SK. Increased FoxP3 and PD-L1 in non-pCR tissue from early stage HER2 positive breast cancer patients treated with trastuzumab-pertuzumab based regimens. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2016. p. 602–602.